مجله سنجش و ایمنی پرتو

مجله سنجش و ایمنی پرتو

مطالعه‌ی تئوری و تجربی اکتیویته اکتینیوم-۲۲۵ بر اساس دختران ساطع کننده گاما در زنجیره واپاشی

نوع مقاله : مقاله پژوهشی

نویسندگان
فاطمه صابری 1
مسلم سوهانی 1
سمانه ذوالقدری 2
سیمین‌دخت شیروانی 3
سارا وثوقی 2
1 دانشکده فیزیک، دانشگاه صنعتی شاهرود، شاهرود، ایران
2 پژوهشکده کاربرد پرتوها، پژوهشگاه علوم و فنون هسته‌ای، سازمان انرژی اتمی ایران، تهران، ایران
3 پژوهشکده چرخه سوخت هسته‌ای، پژوهشگاه علوم و فنون هسته‌ای، سازمان انرژی اتمی ایران، تهران، ایران
10.22052/rsm.2026.258484.1164
چکیده
با گسترش درمان‌های هدفمند نظیر رادیونوکلئیدتراپی، رادیونوکلئیدهای آلفازا از جمله اکتینیوم-۲۲۵ به‌دلیل LET بالا و برد کوتاه، نقش مهمی در درمان تومورهای مقاوم به درمان یافته‌اند. در این مطالعه، رفتار زمانی اکتیویته زنجیره واپاشی اکتینیوم-۲۲۵ با مدل‌سازی عددی معادلات دیفرانسیلی زنجیره واپاشی در نرم‌افزار MATLAB و اندازه‌گیری تجربی با طیف‌سنجی گاما توسط آشکارساز HPGe بررسی شد. نتایج کمی نشان داد اختلاف نسبی بین اکتیویته محاسبات تئوری و مقادیر تجربی استخراج‌شده از دختران گامازا (فرانسیوم ۲۲۱ و بیسموت ۲۱۳) کمتر از 2% بوده و اعمال میانگین وزنی مبتنی بر عدم‌قطعیت‌ها منجر به بهبود معنی‌دار انطباق داده‌ها می‌گردد. همچنین، تحلیل زمانی نشان داد تعادل گذرای هسته‌های فرانسیوم-۲۲۱ و بیسموت-۲۱۳ به‌ترتیب طی کمتر از 1 ساعت و 20 ساعت برقرار می‌شود. بررسی بلندمدت نمونه در بازه شش‌ماهه، عدم وجود ناخالصی رادیونوکلئیدی قابل اندازه‌گیری را تأیید کرد. نتایج این مطالعه نشان می‌دهد مدل‌سازی عددی زنجیره واپاشی می‌تواند ابزاری قابل اعتماد برای برآورد کمی اکتیویته اکتینیوم-۲۲۵ و بهبود محاسبات دزیمتری در آلفا‌درمانی هدفمند باشد.
کلیدواژه‌ها
اکتینیوم-225
نرم‌افزار MATLAB
آشکارساز ژرمانیوم با خلوص بالا (HPGe)

عنوان مقاله English

Theoretical and Experimental Studies of Actinium-225 Based on Gamma-Emitting Daughters in the Decay Chain

نویسندگان English

Fateme Saberi 1
Moslem Sohani 1
Samaneh Zolghadri 2
Simindokht Shirvani 3
Sara Vosoughi 2
1 Faculty of Physics and Nuclear Engineering, Shahrood University of Technology, Shahrood, Iran
2 Radiation Application Research School, Nuclear Science and Technology Research Institute, AEOI, Tehran, Iran
3 Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, AEOI, Tehran, Iran
چکیده English

With the advancement of targeted therapies such as radionuclide therapy, alpha emitting radionuclides, including actinium 225, have gained considerable importance in the treatment of therapy resistant tumors due to their high linear energy transfer (LET) and short particle range. In this study, the time dependent activity behavior of the actinium 225 decay chain was investigated through numerical modeling of the decay chain differential equations using MATLAB, along with experimental measurements performed by gamma ray spectrometry employing an HPGe detector. Quantitative results demonstrated that the relative difference between theoretically calculated activities and experimentally derived values obtained from gamma emitting daughter nuclides (francium 221 and bismuth 213) remained below 2%, and that applying uncertainty weighted averaging led to a significant improvement in the agreement between theoretical and experimental data. Furthermore, temporal analysis indicated that equilibrium for francium 221 and bismuth 213 was established within less than 1 hour and 20 hours, respectively. Long term monitoring of the sample over a six month period confirmed the absence of any measurable radionuclide impurities. These findings demonstrate that numerical modeling of the decay chain provides a reliable tool for the quantitative estimation of actinium 225 activity and for improving dosimetric calculations in targeted alpha therapy.

کلیدواژه‌ها English

Actinium-225
MATLAB softwar
High-Purity Germanium (HPGe) detector
1. WHO. Cancer. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer.
2. F. Bray, J. Ferlay, I. Soerjomataram, RL. Siegel, LA . Torre, A. Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 (6) (2018) 394-424.
3. Daroo Vasalamat. Available at: https://www.daroovasalamat.ir/news/64527.
4. HJ. West, J. Jin. Neoadjuvant therapy. JAMA Oncol. 1 (4) (2015) 550.
5. G.Sgouros. Alpha-particles for targeted therapy. Adv. Drug. Deliv. Rev. 60 (12) (2008) 1402-1406.
6. D. A. Scheinberg, M. R. McDevitt. Actinium-225 in targeted alpha-particle therapeutic applications. Curr. Radiopharm. 4 (4) (2011) 306-320.
7. C. Kratochwil, F. Bruchertseifer, H. Rathke, M. Bronzel, C. Apostolidis, W. Weichert, U. Haberkorn, F. L. Giesel, A. Morgenstern. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J. Nucl. Med. 58 (10) (2017) 1624-1631.
8. R. M. de Kruijff, R. Raavé, A. Kip, J. Molkenboer-Kuenen, A. Morgenstern, F. Bruchertseifer, S. Heskamp, A. G. Denkova. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci. Rep. 9 (1) (2019) 11671.
9. A. P. Bidkar, L. Zerefa, S. Yadav, H. F. VanBrocklin, R. R. Flavell. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 14 (7) (2024) 2969-2992.
10. A. Morgenstern, C. Apostolidis, F. Bruchertseifer. Supply and clinical application of actinium-225 and bismuth-213. Semin. Nucl. Med. 50 (2) (2020) 119-123.
 11. P. E. Borchardt, R. R. Yuan, M. Miederer, M. R. McDevitt, D. A. Scheinberg. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63 (16) (2003) 5084-5090.
12. A. M. Ballangrud, W. H. Yang, S. Palm, R. Enmon, P. E. Borchardt, V. A. Pellegrini, M. R. McDevitt, D. A. Scheinberg, G. Sgouros. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin. Cancer Res. 10 (13) (2004) 4489-4497.
13. H. Yang, C. Zhang, Z. Yuan, C. Rodriguez-Rodriguez, A. Robertson, V. Radchenko, R. Perron, D. Gendron, P. Causey, F. Gao. Synthesis and evaluation of a macrocyclic actinium-225 chelator, quality control and in vivo evaluation of 225Ac-crown-αMSH peptide. Chem. Eur. J. 26 (50) (2020) 11435-11440.
14. T. Watabe, Y. Liu, K. Kaneda-Nakashima, Y. Shirakami, T. Lindner, K. Ooe, A. Toyoshima, K. Nagata, E. Shimosegawa, U. Haberkorn, C. Kratochwil. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J. Nucl. Med. 61 (4) (2020) 563-569.
15. F. Reissig, K. Zarschler, Z. Novy, M. Petrik, K. Bendova, D. Kurfurstova, J. Bouchal, M. C. Ludik, F. Brandt, K. Kopka, M. Khoylou. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin. Theranostics. 12 (17) (2022) 7203-7215.
16. M. R. Alam, S. B. Singh, S. Thapaliya, S. Shrestha, S. Deo, K. Khanal. A review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging theranostic agents in prostate cancer. Cureus 14 (9) (2022) e29369.
17. C. C. Oliveira-Silva, M. S. Maillard, R. Silva, L. V. Sá. Dosimetry at cellular level for the alpha-emitting radionuclides actinium-225, astatine-211 and radium-223 for bone metastasis cells from castration resistant prostate cancer. Phys. Med. Biol. 69 (20) (2024) 205004.
18. K. Ramonaheng, K. Banda, M. Qebetu, P. Goorhoo, L. Legodi, K. Masogo, Y. Seebarruth, S. Mdanda, S. Sibiya, Y. Mzizi, C. Davis, L. Smith, H. Ndlovu, J. Kabunda, A. Maes, C. Van de Wiele, A. Al-Ibraheem, M. Sathekge. Clinical image-based dosimetry of actinium-225 in targeted alpha therapy. Cancers (Basel) 18 (2) (2026) 321.
19. S. Zhang, X. Wang, X. Gao, X. Chen, L. Li, G. Li, C. Liu, Y. Miao, R. Wang, K. Hu. Radiopharmaceuticals and their applications in medicine. Signal Transduct. Target. Ther. 10 (1) (2025) 1.
20. International Atomic Energy Agency (IAEA). Isotope Browser [mobile application]. Available at: https://play.google.com/store/apps/details?id=iaea.nds.nuclides&hl=en (version 22 October 2024).
21. G. Suliman, S. Pommé, M. Marouli, R. Van Ammel, H. Stroh, V. Jobbágy, J. Paepen, A. Dirican, F. Bruchertseifer, C. Apostolidis, A. Morgenstern. Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series. Appl. Radiat. Isot. 77 (2013) 32-37.
22. L. Safarzadeh, M. Ghannadi-Maragheh, A. Anvari, S. Aghamiri, S. Shirvani-Arani, A. Bahrami-Samani. Production and quality control of175Yb-EDTMP for pain palliation of bone metastases. J. Nucl. Sci. Technol. 34 (2) (2012) 48-55. [In Persian]
23. E. L. Hooijman, V. Radchenko, S. W. Ling, M. Konijnenberg, T. Brabander, S. L. Koolen, E. de Blois. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-) clinical perspectives. EJNMMI Radiopharm Chem. 9 (1) (2024) 9.
24. D. S. Abou, P. Zerkel, J. Robben, M. McLaughlin, T. Hazlehurst, D. Morse, T. J. Wadas, D. N. Pandya, R. Oyama, G. Gaehle, M. L. Nickels. Radiopharmaceutical quality control considerations for accelerator-produced actinium therapies. Cancer Biother Radiopharm 37 (5) (2022) 355-63.
25. R. Shukurov, M. Veliyev, Z. Dadashov, J. İsayev, F. Novruzov.Labeling process and quality control results of 225Ac-PSMA-617 for targeted alpha particle therapy for metastatic prostate cancer. J. Nucl. Med. 60 (Suppl. 1) (2019) 1611.
26. International Atomic Energy Agency (IAEA). Production and Quality Control of Actinium-225 Radiopharmaceuticals. IAEA-TECDOC-2057. International Atomic Energy Agency, Vienna, Austria, 2024.
27. M. Sathekge, F. Bruchertseifer, M. Vorster, I. O. Lawal, K. Mokoala, J. Reed, L. Maseremule, H. Ndlovu, K. Hlongwa, A. Maes, A. Morgenstern, C. Van de Wiele. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur. J. Nucl. Med. Mol. Imaging. 50 (7) (2023) 2210-8.
28. International Atomic Energy Agency (IAEA). Quantifying Uncertainty in Nuclear Analytical Measurements. IAEA-TECDOC-1401. International Atomic Energy Agency, Vienna, Austria, 2004.
29. Joint Committee for Guides in Metrology (JCGM). Evaluation of Measurement Data—Guide to the Expression of Uncertainty in Measurement. JCGM 100:2008 (GUM 1995 with Minor Corrections). Joint Committee for Guides in Metrology, Sèvres, France (2008) 134 pp.
30. D. Castillo Seoane, M. De Saint-Hubert, S. Ahenkorah, C. Saldarriaga Vargas, M. Ooms, L. Struelens, M. Koole. Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter. EJNMMI Radiopharm. Chem. 7 (1) (2022) 28.